BACKGROUND AND OBJECTIVE: To determine the prophylactic and therapeutic value of a single subthreshold 810-nanometer laser treatment in patients with high risk drusen as a manifestation of dry age-related macular degeneration in both eyes. PATIENTS AND METHODS: The Prophylactic Treatment of Age-related Macular Degeneration study enrolled 1,278 eyes of 639 participants who were 50 years or older with at least 5 drusen 63 microm or more in diameter in each eye. Treatment consisted of the placement of an annular grid of 48 extrafoveal, subthreshold 810-nm diode laser applications centered at but sparing the foveola in one eye of each participant, with the fellow eye serving as a control. Development of choroidal neovascularization and change in best-corrected visual acuity were compared between treated and untreated eyes. RESULTS: Subthreshold laser treatment did not decrease the incidence of choroidal neovascularization in treated versus untreated eyes. A modest visual acuity benefit in treated eyes was found at 24 months (1.5 letter difference; P = .04) and in the treated eyes of participants with a baseline visual acuity between 20/32 and 20/63 (4.0 letter difference; P = .0034). However, this treatment effect was not sustained at 3 years. CONCLUSION: A single subthreshold 810-nanometer laser treatment to eyes of participants with bilateral high risk drusen is not an effective prophylactic strategy against choroidal neovascularization. Copyright 2009, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To determine the prophylactic and therapeutic value of a single subthreshold 810-nanometer laser treatment in patients with high risk drusen as a manifestation of dry age-related macular degeneration in both eyes. PATIENTS AND METHODS: The Prophylactic Treatment of Age-related Macular Degeneration study enrolled 1,278 eyes of 639 participants who were 50 years or older with at least 5 drusen 63 microm or more in diameter in each eye. Treatment consisted of the placement of an annular grid of 48 extrafoveal, subthreshold 810-nm diode laser applications centered at but sparing the foveola in one eye of each participant, with the fellow eye serving as a control. Development of choroidal neovascularization and change in best-corrected visual acuity were compared between treated and untreated eyes. RESULTS: Subthreshold laser treatment did not decrease the incidence of choroidal neovascularization in treated versus untreated eyes. A modest visual acuity benefit in treated eyes was found at 24 months (1.5 letter difference; P = .04) and in the treated eyes of participants with a baseline visual acuity between 20/32 and 20/63 (4.0 letter difference; P = .0034). However, this treatment effect was not sustained at 3 years. CONCLUSION: A single subthreshold 810-nanometer laser treatment to eyes of participants with bilateral high risk drusen is not an effective prophylactic strategy against choroidal neovascularization. Copyright 2009, SLACK Incorporated.
Authors: Quan Findlay; Andrew I Jobling; Kirstan A Vessey; Ursula Greferath; Joanna A Phipps; Robyn H Guymer; Erica L Fletcher Journal: Eye (Lond) Date: 2018-03-09 Impact factor: 3.775
Authors: Giuseppe Querques; Maria Vittoria Cicinelli; Alessandro Rabiolo; Luigi de Vitis; Riccardo Sacconi; Lea Querques; Francesco Bandello Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-11-25 Impact factor: 3.117
Authors: Brian C Toy; Nupura Krishnadev; Maanasa Indaram; Denise Cunningham; Catherine A Cukras; Emily Y Chew; Wai T Wong Journal: Am J Ophthalmol Date: 2013-07-03 Impact factor: 5.258
Authors: Jan Tode; Elisabeth Richert; Stefan Koinzer; Alexa Klettner; Claus von der Burchard; Ralf Brinkmann; Ralph Lucius; Johann Roider Journal: Transl Vis Sci Technol Date: 2018-05-01 Impact factor: 3.283
Authors: João Pedro Marques; Miguel Costa; Pedro Melo; Carlos Manta Oliveira; Isabel Pires; Maria Luz Cachulo; João Figueira; Rufino Silva Journal: ISRN Ophthalmol Date: 2013-07-30